Alternatives to Venofer If You Can't Fill Your Prescription

Venofer (iron sucrose injection) has been the go-to IV iron replacement for chronic kidney disease patients for more than 25 years. But when supply runs low at your dialysis center or infusion clinic — as happened during the June–November 2024 allocation period — you and your care team may need to consider other options.

The good news: several FDA-approved IV iron products can substitute for Venofer, each with different dosing schedules, indications, costs, and insurance requirements. Here's what you need to know about each one so you can have an informed conversation with your nephrologist.

Why IV Iron Cannot Be Replaced With Oral Iron Alone

Before looking at alternatives, it's important to understand why switching to oral iron supplements isn't a simple solution for most CKD patients. In chronic kidney disease, the gut often does not absorb oral iron efficiently due to elevated hepcidin levels and gastrointestinal side effects. Moreover, the inflammatory state associated with CKD impairs iron utilization. This is why intravenous iron is the standard of care for iron deficiency anemia in CKD patients, and why a switch to oral iron is rarely adequate during a Venofer supply shortage.

Generic Iron Sucrose: The Closest Substitute

The simplest alternative to Venofer is FDA-approved generic iron sucrose injection. Generic iron sucrose contains the same active ingredient at the same concentration (20 mg elemental iron per mL) and is considered therapeutically equivalent to Venofer by the FDA. Many dialysis centers and hospitals already routinely use generic iron sucrose. If your clinic has a supply issue with branded Venofer specifically, ask whether generic iron sucrose is available — it may already be in their formulary.

Ferrlecit (Sodium Ferric Gluconate): For Hemodialysis Patients on ESA

Ferrlecit (sodium ferric gluconate) is FDA-approved for iron deficiency anemia in adult and pediatric patients (≥6 years) with CKD receiving hemodialysis who are also on erythropoiesis-stimulating agent (ESA) therapy. The typical adult dose is 125 mg IV per dialysis session, and most patients require a cumulative dose of 1,000 mg over 8 dialysis sessions.

Ferrlecit has a well-established safety profile similar to iron sucrose and has been used in dialysis settings for decades. It's generally available without step therapy requirements at most insurers.

Feraheme (Ferumoxytol): Fewer Visits, Higher Cost

Feraheme (ferumoxytol) is FDA-approved for IDA in adults 18 and older who cannot tolerate oral iron or have CKD. It is given as two 510 mg IV injections, 3–8 days apart — a complete treatment course in just two visits compared to 5–10 visits for iron sucrose. A randomized head-to-head trial showed comparable hemoglobin improvement between Feraheme and Venofer at 5 weeks.

The tradeoffs: Feraheme is significantly more expensive than Venofer, and many private insurers (including Aetna and UnitedHealthcare) require prior authorization and evidence of failure or intolerance to less expensive IV iron products like Venofer before they'll cover it.

39,483+ patients found their medications in stock

39K+

Find Venofer In Stock Today →

Injectafer (Ferric Carboxymaltose): High Dose, High Cost

Injectafer (ferric carboxymaltose) is indicated for IDA in adults with intolerance or unsatisfactory response to oral iron, or for adults with non-dialysis-dependent CKD. It is also the first IV iron approved for IDA in patients with heart failure (New York Heart Association class II/III). Dosing: 750 mg IV twice, separated by at least 7 days (cumulative 1,500 mg per course), or 15 mg/kg as a single dose.

Like Feraheme, Injectafer typically requires prior authorization at most private insurers. Its higher per-dose cost — roughly 5 times or more than a Venofer course — makes it a less economical choice for routine use. However, for patients who need rapid iron repletion with fewer clinic visits, it may be appropriate.

INFeD (Iron Dextran): One Infusion, Higher Risk

INFeD (low molecular weight iron dextran) allows the full 1,000 mg course to be given as a single infusion — maximally convenient in terms of visits. However, iron dextran carries a higher risk of serious anaphylactic reactions compared to iron sucrose, and requires a 25 mg test dose before the full infusion. Most guidelines reserve iron dextran for patients who cannot tolerate other IV iron formulations.

Skip the calls, skip the stress.

Find Venofer In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Monoferric (Ferric Derisomaltose): A Newer Option

Monoferric (ferric derisomaltose) is the newest IV iron product on the U.S. market. It can be given as a single high-dose infusion (up to 1,000 mg) or two doses. While convenient, it requires prior authorization from most insurers, and some payer policies (including UnitedHealthcare) do not consider it medically necessary given the availability of less expensive alternatives like Venofer.

Quick Comparison: Venofer vs. IV Iron Alternatives

Venofer (iron sucrose): 100–200 mg per session, 5–10 visits, low cost, no prior auth for dialysis patients

Generic iron sucrose: Same as Venofer, therapeutically equivalent, often lower cost

Ferrlecit: 125 mg per session, 8 sessions, for hemodialysis patients on ESA only

Feraheme: 510 mg x2 doses, just 2 visits, higher cost, usually requires prior auth

Injectafer: 750 mg x2 doses, 2 visits, highest cost, requires prior auth

INFeD: 1,000 mg in 1 visit, requires test dose, higher anaphylaxis risk

What to Do Next

If Venofer is unavailable at your infusion center, the first step is always to talk with your nephrologist. They can prescribe an appropriate alternative and handle the prior authorization process with your insurer. Read our guide on why Venofer is hard to find for background, and visit medfinder.com to search for providers near you who have iron sucrose or alternatives in stock.